Anne-Marie Koop

316 14. Trip P, Rain S, Handoko ML, DerBruggen C Van, Bogaard HJ, Marcus JT, Boonstra A, Westerhof N, Vonk-Noordegraaf A, S De Man F. Clinical relevance of right ventricular diastolic stiffness in pulmonary hypertension. Eur Respir J 2015;45:1603–1612. 15. Rain S, Handoko ML, Trip P, Gan CT-J, Westerhof N, Stienen GJ, Paulus WJ, Ottenheijm CAC, Marcus JT, Dorfmüller P, Guignabert C, Humbert M, Macdonald P, Remedios C Dos, Postmus PE, Saripalli C, Hidalgo CG, Granzier HL, Vonk-Noordegraaf A, Velden J Van Der, Man FS De. Right ventricular diastolic impairment in patients with pulmonary arterial hypertension. Circulation F.S. De Man, Department of Pulmonology, VU University Medical Center, Institute for Cardiovascular Research, 1081 HV Amsterdam, Netherlands; 2013;128:2016–2025. 16. Chamsi-Pasha MA, ZhanY, Debs D, Shah DJ. CMR in the Evaluation of Diastolic Dysfunction and Phenotyping of HFpEF: Current Role and Future Perspectives. JACC Cardiovasc Imaging Elsevier; 2020;13:283–296. 17. Cohn JN, Tognoni G. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure. N Engl J Med 2001;345:1667–1675. 18. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Östergren J, Yusuf S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme. Lancet 2003;362:759–766. 19. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093–1129. 20. Osorio JC, StanleyWC, Linke A, Castellari M, Diep QN, Panchal AR, Hintze TH, Lopaschuk GD, Recchia FA. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-α in pacing-induced heart failure. Circulation 2002;106:606–612. 21. Chandler MP, Kerner J, Huang H, Vazquez E, Reszko A, Martini WZ, Hoppel CL, Imai M, Rastogi S, Sabbah HN, Stanley WC. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol - Hear Circ Physiol 2004;287:1538–1543. 22. Remondino A, Rosenblatt-Velin N, Montessuit C, Tardy I, Papageorgiou I, Dorsaz PA, Jorge-Costa M, Lerch R. Altered expression of proteins of metabolic regulation during remodeling of the left ventricle after myocardial infarction. J Mol Cell Cardiol 2000;32:2025– 2034. 23. Nascimben L, Ingwall JS, Lorell BH, Pinz I, Schultz V, Tornheim K, Tian R. Mechanisms for increased glycolysis in the hypertrophied rat heart. Hypertension 2004;44:662–667. 24. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 2001;104:2923–2931. 25. Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ, Stone CK. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia- heptadecanoic acid and [18F]FDG in patients with congestive heart failure. J Nucl Med 2001;42:55–62. 26. Graham BB, Kumar R, Mickael C, Sanders L, Gebreab L, Huber KM, Perez M, Smith-Jones P, Serkova NJ, Tuder RM. Severe pulmonary hypertension is associated with altered right ventricle metabolic substrate uptake. Am J Physiol - Lung Cell Mol Physiol B.B. Graham, Division of Pulmonary Sciences and Critical Care Medicine, Univ. of Colorado Denver, Aurora, United States; 2015;309:L435–L440.